PLUVICTO Drug Patent Profile

When do Pluvicto patents expire, and when can generic versions of Pluvicto launch?

Pluvicto is a drug marketed by Novartis and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and thirty-nine patent family members in thirty-nine countries.

The generic ingredient in PLUVICTO is lutetium lu-177 vipivotide tetraxetan. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the lutetium lu-177 vipivotide tetraxetan profile page.

DrugPatentWatch^® Generic Entry Outlook for Pluvicto

Pluvicto was eligible for patent challenges on March 23, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 17, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for PLUVICTO

International Patents:	139
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	9
Drug Prices:	Drug price information for PLUVICTO
What excipients (inactive ingredients) are in PLUVICTO?	PLUVICTO excipients list
DailyMed Link:	PLUVICTO at DailyMed

See drug prices for PLUVICTO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PLUVICTO

NDA:

215833

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PLUVICTO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
M.D. Anderson Cancer Center	NA
GE Healthcare	NA
Novartis	PHASE1

See all PLUVICTO clinical trials

Pharmacology for PLUVICTO

Drug Class	Radioligand Therapeutic Agent
Mechanism of Action	Radioligand Activity

US Patents and Regulatory Information for PLUVICTO

PLUVICTO is protected by five US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes			Y	Y
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes
Novartis	PLUVICTO	lutetium lu-177 vipivotide tetraxetan	SOLUTION;INTRAVENOUS	215833-001	Mar 23, 2022		RX	Yes	Yes			Y	Y

International Patents for PLUVICTO

When does loss-of-exclusivity occur for PLUVICTO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Chile

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

France

Georgia, Republic of

Germany

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Morocco

Netherlands

New Zealand

Peru

Philippines

Poland

Portugal

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PLUVICTO around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	4095130
Malaysia	188934	LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
Georgia, Republic of	AP202114132	LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER
Japan	7079355
Lithuania	PA2024522

Supplementary Protection Certificates for PLUVICTO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4095130	C20240024	Finland
4095130	2024C/528	Belgium		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; AUTHORISATION NUMBER AND DATE: EU/1/22/1703 20221212
4095130	C04095130/01	Switzerland		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTID TETRAXETAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68684 24.02.2023
4095130	23/2024	Austria		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703 (MITTEILUNG) 20221212
4095130	122024000038	Germany		PRODUCT NAME: (177LU)LUTETIUMVIPIVOTIDTETRAXETAN; REGISTRATION NO/DATE: EU/1/22/1703 20221209

Market Dynamics and Financial Trajectory for PLUVICTO

Last updated: January 7, 2026

Summary

PLUVICTO (generic name: tucatinib) is an oral tyrosine kinase inhibitor developed by Seattle Genetics and plans for commercialization by its partner, Seagen Inc. Approved by the FDA in April 2021 for metastatic HER2-positive breast cancer, it has rapidly established itself as a pivotal drug within a niche, high-value oncology market. This report comprehensively examines the market landscape, regulatory status, competitive environment, financial projections, and future growth drivers for PLUVICTO.

---

What is PLUVICTO, and What Are Its Therapeutic Indications?

Product Overview

Attribute	Details
Generic Name:	Tucatinib
Brand Name:	PLUVICTO
Drug Class:	HER2-targeted tyrosine kinase inhibitor (TKI)
Mechanism of Action:	Selectively inhibits HER2 kinase activity, impeding tumor growth
Formulation:	Oral tablet (225 mg)

Indications

• Metastatic HER2-positive breast cancer, specifically for patients who have received trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1)
• Often used in conjunction with capecitabine (a chemotherapeutic agent)

Approval Date & Regulatory Milestones

• FDA Approval: April 2021
• EMA & Other Markets: Pending, with early-stage considerations for regulatory submissions in Europe and Asia

---

Market Landscape for HER2-Positive Breast Cancer

Global Incidence and Market Size

Metric	2021 Estimates	Notes
Global Breast Cancer Incidence	2.3 million cases	WHO, 2022
HER2-Positive Subset	~20-25%	Of all breast cancers (approx. 460,000 annually)
Target Patient Population (US & EU)	~115,000 patients/year	Based on epidemiology and treatment patterns

Treatment Landscape & Competitive Positioning

Competitors	Approvals & Indications	Key Differentiators
Kadcyla (ado-trastuzumab emtansine)	HER2-positive breast cancer	Antibody-drug conjugate, established standard
Perjeta (pertuzumab) + Herceptin (trastuzumab)	First-line HER2+ therapy	Monoclonal antibodies
Neratinib (Nerkenza)	Extended adjuvant therapy	Oral TKI, but less selective than tucatinib
Tucatinib (PLUVICTO)	Approved for metastatic HER2+ breast cancer	Selectivity for HER2, activity in brain metastases

Market Share Dynamics (2021-2023)

• PLUVICTO quickly gained significant uptake due to its targeted mechanism and improved CNS activity profile.

---

Regulatory and Reimbursement Environment

FDA Approval & Labeling

• Indication: Combination with capecitabine and trastuzumab for advanced HER2+ breast cancer after 2+ prior anti-HER2 regimens
• Key Trials: HER2CLIMB study (NCT02614780), demonstrating efficacy and CNS penetration

Reimbursement Trends

Factor	Impact	Notes
Coverage	Broad in the US	Established via Medicare and private insurers
Pricing	Approx. $15,000/month	Reflects value-based pricing for orphan oncology
Cost-Effectiveness	Favorable in metastatic setting	Assessed via quality-adjusted life years (QALYs) and survival benefits

Policy Drivers & Challenges

• Payer emphasis on survival benefits and CNS efficacy
• Increasing demand for oral targeted therapies impacting outpatient care costs
• Potential negotiations on pricing as more competitors enter the space

---

Financial Trajectory & Market Penetration

Revenue Projections (2023-2030)

Year	Estimated Revenue (USD millions)	Assumptions	Sources
2023	$250-300M	Initial uptake in US, expanding globally	Seagen's Q2 2023 reported sales data
2024	$500-600M	Broadened access, extended indications	EMEA submissions, real-world data
2025	$1B+	Possible approval in earlier-line settings	Market expansion, combo therapies
2030	$2-3B	Growing global adoption, new indications	Competitive differentiation and CNS efficacy

Key Growth Drivers

Driver	Impact	Details
CNS Penetration & Brain Metastases	Strongest differentiator	Clinical data shows significant activity, expanding its use in patients with CNS metastases
Combination Therapies	Larger patient pool	Potential approvals for earlier-line settings and into other HER2-positive cancers (e.g., gastric)
Market Expansion	Geographic	Entry into Asian, Latin American, and European markets
Competitive Landscape Maturation	Increased sales	As new competitors emerge, differentiation becomes key

Pricing Strategy & Reimbursement

• Tightly aligned with value-based models; premium pricing justified by survival and CNS benefits.
• Growing adoption of patient assistance programs and biosimilars may impact long-term pricing strategies.

---

Future Outlook: Opportunities and Challenges

Opportunities

• Broader Indications: Potential for adjuvant or neoadjuvant settings & gastric cancers.
• Combination with Emerging Therapies: Immune checkpoint inhibitors, other targeted agents.
• Global Market Expansion: Focused efforts in Asia-Pacific and emerging markets.
• Real-World Evidence (RWE): Accelerate payer acceptance and clinician adoption.

Challenges

• Competitive Pressures: Emergence of novel HER2-targeted agents, biosimilars.
• Pricing & Reimbursement: Sustaining premium pricing amid healthcare cost pressures.
• Regulatory Risks: Delays or denials in new indications, regulatory policy shifts.
• Market Penetration: Adoption rates influenced by clinician familiarity and competing regimens.

---

Comparison with Other HER2-Targeted Agents

Attribute	PLUVICTO (Tucatinib)	Kadcyla	Perjeta + Herceptin	Neratinib
Approval Year	2021	2013	2012	2017
Mechanism	Selective HER2 TKI	Antibody-drug conjugate	Monoclonal antibodies	Pan-HER TKI
Main Use	Metastatic HER2+ / CNS metastases	Adjuvant/metastatic	First-line metastatic	Extended adjuvant therapy
Pricing (approx.)	$15,000/month	$10,000/month	$20,000/month	$12,000/month
Strengths	CNS activity, oral	Proven efficacy	Standard-of-care	Extended therapy options

---

FAQs on PLUVICTO Market and Financial Outlook

Q1: What factors contributed to the rapid adoption of PLUVICTO post-approval?
A: Its demonstrated CNS penetration, favorable safety profile, and addition to the HER2-targeted therapeutic arsenal have driven early adoption, especially among clinicians managing brain metastases.

Q2: How does the selectivity of tucatinib influence its market position?
A: High selectivity minimizes off-target effects and enhances efficacy against CNS metastases, providing a competitive advantage over less selective TKIs.

Q3: What is the potential impact of biosimilars or generics on PLUVICTO’s market share?
A: Currently, tucatinib has no generic equivalents; however, patent expiration or biosimilar entry could pressure prices and erode margins, emphasizing the importance of pipeline expansion.

Q4: Which emerging indications could significantly expand PLUVICTO’s market?
A: Early research into adjuvant settings, gastric cancers, and combined regimens with immunotherapies may broaden its usage, potentially increasing revenue fivefold over the next decade.

Q5: What are the key hurdles for global market penetration of PLUVICTO?
A: Regulatory approvals, local pricing negotiations, healthcare infrastructure, and clinician familiarity are primary hurdles. Tailored strategies, including local clinical trials and strategic partnerships, are essential.

---

Key Takeaways

• Market Positioning: PLUVICTO’s unique CNS activity positions it as a critical agent within metastatic HER2-positive breast cancer treatment, supported by strong clinical evidence.
• Revenue Potential: Projections indicate a trajectory toward $2-3 billion in annual revenue by 2030, driven by expanding indications and geographical reach.
• Competitive Environment: While currently benefiting from a first-mover advantage in CNS metastases, competitive pressures from other novel HER2 agents and biosimilars necessitate continuous innovation.
• Regulatory & Reimbursement: Favorable regulatory decisions and value-based reimbursement strategies will underpin sustained market success.
• Growth Strategies: Diversifying indications, expanding globally, leveraging real-world data, and optimizing patient access will be critical for maximizing PLUVICTO’s financial trajectory.

---

References

1. WHO. Global Cancer Observatory. Breast Cancer Factsheet. 2022.
2. Seagen Inc. Quarterly Financial Reports. 2023.
3. FDA. Prescribing Information: PLUVICTO. April 2021.
4. HER2CLIMB Trial Data. The New England Journal of Medicine. 2021.
5. Market Research Future. Oncology Drugs Market. 2022.

---

Disclaimer: This analysis consolidates publicly available data and market intelligence as of early 2023. Market dynamics are subject to rapid change; thus, future projections should be interpreted as estimates contingent on evolving clinical, regulatory, and competitive developments.